Richard S. Finn, MD, on HCC: Atezolizumab Plus Bevacizumab vs Sorafenib

January 21, 2021 By The ASCO Post Staff

Richard S. Finn, MD, of the UCLA Medical Center, discusses updated results from the IMbrave 150 study, which showed atezolizumab plus bevacizumab provides the longest overall survival seen in a front-line phase III study in advanced hepatocellular carcinoma, confirming this combination as the standard of care for patients with previously untreated, unresectable disease (Abstract 267).

Related Content